Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of JAK inhibition on RA-related bone and vascular comorbidities
2015-002523-26Phase 4Completed
- Sponsor
- Arthritis Alapítvány
- Start
- Nov 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tofacitinib in rheumatoid arthritis (RA), sponsored by Arthritis Alapítvány. Primary endpoint: Surrogate markers of vascular pathology at 12 months. Started Nov 2015; status: completed.
02
Drugs
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2015-002523-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002523-26.